Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up After Insider Buying Activity

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $14.52, but opened at $15.23. Pulse Biosciences shares last traded at $15.47, with a volume of 61,608 shares traded.

Specifically, Director Robert W. Duggan bought 12,800 shares of the company’s stock in a transaction dated Wednesday, September 11th. The stock was acquired at an average cost of $14.77 per share, with a total value of $189,056.00. Following the acquisition, the director owned 47,564,000 shares in the company, valued at approximately $702,520,280. This represents a 0.03% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert W. Duggan purchased 34,659 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were acquired at an average price of $14.66 per share, for a total transaction of $508,100.94. Following the completion of the transaction, the director owned 47,551,200 shares in the company, valued at $697,100,592. The trade was a 0.07% increase in their ownership of the stock. The disclosure for this purchase can be found here. In other Pulse Biosciences news, Director Robert W. Duggan purchased 145,140 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $14.41 per share, for a total transaction of $2,091,467.40. Following the transaction, the director directly owned 47,709,140 shares in the company, valued at approximately $687,488,707.40. The trade was a 0.31% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

Wall Street Analyst Weigh In

Separately, Oppenheimer started coverage on Pulse Biosciences in a research report on Monday, July 7th. They set an “outperform” rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $22.00.

Pulse Biosciences Trading Up 8.4%

The company has a 50 day moving average price of $15.49 and a 200 day moving average price of $16.15. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -14.99 and a beta of 1.68.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its stake in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the period. AlphaQuest LLC grew its stake in shares of Pulse Biosciences by 68.0% during the first quarter. AlphaQuest LLC now owns 3,116 shares of the company’s stock worth $50,000 after purchasing an additional 1,261 shares during the period. PNC Financial Services Group Inc. acquired a new stake in shares of Pulse Biosciences during the first quarter worth $90,000. Finally, GAMMA Investing LLC grew its stake in shares of Pulse Biosciences by 2,203.1% during the first quarter. GAMMA Investing LLC now owns 6,034 shares of the company’s stock worth $97,000 after purchasing an additional 5,772 shares during the period. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.